Advocacy intelligence hub — real-time data for patient organizations
Beijing Tsinghua Chang Gung Hospital — NA
Cancer Institute and Hospital, Chinese Academy of Medical Sciences — PHASE2
Istituto Oncologico Veneto IRCCS
Memorial Sloan Kettering Cancer Center — PHASE2
National Cancer Institute (NCI) — PHASE2
University Hospital, Geneva — PHASE1
National Cancer Institute (NCI) — PHASE1, PHASE2
MedImmune LLC — PHASE2
Alimta: FDA approved
Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery
Sclerosol Intrapleural Aerosol: FDA approved
Prevention of recurrence of malignant pleural effusions in symptomatic patients.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance2
Sclerosol Intrapleural Aerosol
Sciarra Laboratories, Inc.
Blenoxane
Bristol-Myers Squibb Pharmaceutical Research Institute
Patient Assistance Programs2
Alimta
(pemetrexed disodium)Orphan drugEli Lilly and Company
12.1 Mechanism of Action ALIMTA is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replicati...
Sclerosol Intrapleural Aerosol
(Sterile talc powder)Orphan drugSciarra Laboratories, Inc.
Blenoxane
(Bleomycin sulfate)Orphan drugBristol-Myers Squibb Pharmaceutical Research Institute
Mechanism of Action Although the exact mechanism of action of bleomycin is unknown, available evidence indicates that the main mode of action is the i...
OPDIVO� and YERVOY�
(nivolumab and ipilimumab)Orphan drugstandardBristol-Myers Squibb Company
Yervoy
(ipilimumab)Orphan drugstandardBristol-Myers Squibb Company
CTLA-4-directed Blocking Antibody [EPC]
12.1 Mechanism of Action CTLA-4 is a negative regulator of T-cell activity. Ipilimumab is a monoclonal antibody that binds to CTLA-4 and blocks the in...
KEYTRUDA
(pembrolizumab)Orphan drugstandardMSD International Business GmbH
Endoglycosidase [EPC]
12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytoki...
Genomic sequencing of multicystic mesothelioma finds cohesin complex mutations associated with disease recurrence in patients referred for cytoreductive surgery and HIPEC.
Multicystic mesothelioma (MCM) is a rare disease and there is debate about it's neoplastic nature with a spectrum of disease behaviour and little known about the genomic profile. In contrast, the geno...
Ascorbic Acid Analog 6-Deoxy-6- 18 F-Fluoro-l-Ascorbic Acid PET Imaging of 23 Various Cancer Types.
High-dose ascorbic acid (AA) has shown promise as an adjunctive treatment for various cancers because of its prooxidant cytotoxicity at high concentrations and its multitargeting effects. However, ide...
Ten-year of French multicentric experience in the management of peritoneal mesothelioma with 924 patients.
Diffuse malignant peritoneal mesothelioma (DMPM) is a rare disease for which only selected patients are eligible for cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)....
Pretreatment volume-based 18 F-FDG PET/CT parameters as prognostic indicators in malignant peritoneal mesothelioma patients.
This study was conducted to examine relationships of pretreatment volume-based quantitative 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) parameters wit...
Novel EWSR1::TEAD3 Fusion in an Adolescent With a Highly Aggressive Peritoneal Mesothelioma.
Malignant peritoneal mesothelioma (MPM) is an exceptionally rare entity in children and adolescents, exhibiting distinct clinicopathological features compared to its adult counterpart. Unlike adult ca...
Analysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study.
To investigate the efficacy and safety of pemetrexed/platinum-based chemotherapy combined with or without bevacizumab after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (...
Hedy Kindler
University of Chicago Comprehensive Cancer Center
📍 CHICAGO, IL
Raffit Hassan, M.D.
National Cancer Institute (NCI)
David L Bartlett, MD
University of Pittsburgh
Andrew M Blakely, M.D., STNA
National Cancer Institute (NCI)
📍 COLUMBUS, OH
Aaron S Mansfield
Alliance for Clinical Trials in Oncology
Kiran Turaga, MD
University of Chicago
📍 CHICAGO, IL